Retreatment of Recurrent Dupuytren's Contractures

This study has been completed.
Information provided by (Responsible Party):
Auxilium Pharmaceuticals Identifier:
First received: December 17, 2011
Last updated: February 4, 2015
Last verified: July 2014

The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.

Condition Intervention Phase
Dupuytren's Disease
Biological: XIAFLEX / XIAPEX
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe

Resource links provided by NLM:

Further study details as provided by Auxilium Pharmaceuticals:

Primary Outcome Measures:
  • Percent Change in Degree of Flexion From Baseline [ Time Frame: 30 days after the last injection of AA4500 ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: March 2012
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: XIAFLEX / XIAPEX MP Joint
Up to three injections of XIAFLEX / XIAPEX 0.58 mg
Biological: XIAFLEX / XIAPEX
up to three 0.58 mg injections
Other Names:
  • AA4500
  • collagenase clostridium histolyticum
Experimental: XIAFLEX / XIAPEX PIP Joint
Up to three injections of XIAFLEX / XIAPEX 0.58 mg
Biological: XIAFLEX / XIAPEX
up to three 0.58 mg injections
Other Names:
  • AA4500
  • collagenase clostridium histolyticum

Detailed Description:

Open-label, Phase 4 study in subjects who are currently participating in the long-term follow-up study (ie, AUX-CC-860) in the United States, Australia, or Europe and who have recurrence of contracture (ie, joint contracture increases by at least 20 degrees compared with the Day 30 value after the last injection in a Phase 3 Auxilium-sponsored study and a palpable cord present) in a joint that was effectively treated (ie, reduction in contracture to 5 degrees or less 30 days after the last injection) with AA4500 in a Phase 3 Auxilium-sponsored study.

Subjects who experience recurrence of contracture in one or more effectively treated joints may be enrolled in this retreatment study after the investigator determines subject eligibility and after informed consent has been obtained. The investigator will treat the cord affecting the recurrent joint with up to three injections. Only one recurrent joint will be treated in this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent
  2. Be currently participating in the AUX-CC-860 follow-up study
  3. Have at least one joint with all of the following:

    • The joint was effectively treated (had a correction to 5 degrees or less at the Day 30 evaluation after the last injection of AA4500) in a previous Auxilium Phase 3 study
    • The effectively treated joint has an increase in contracture of at least 20 degrees compared with the Day 30 value after the last injection of AA4500 in a previous Auxilium Phase 3 study
    • A palpable cord is present in the joint to be treated
  4. Be able to comply with the study visit schedule as specified in the protocol

Exclusion Criteria:

  1. Is a pregnant or lactating female or female intending to become pregnant during the study
  2. Has hypersensitivity to AA4500 or any of the AA4500 excipients
  3. Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for equal to or less than 150 mg aspirin daily and over-the-counter nonsteroidal antiinflammatory drugs [NSAIDs]) within 7 days before injection of AA4500
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01498640

United States, Arizona
HOPE Research Institute
Phoenix, Arizona, United States, 85050
United States, Illinois
Rockford Orthopedic Associates
Rockford, Illinois, United States, 61107
United States, Indiana
The Indiana Hand to Shoulder Center
Indianapolis, Indiana, United States, 46260
United States, Michigan
Marquette General Health System
Marquette, Michigan, United States, 49855
United States, New York
East River Professional Building
New York, New York, United States, 10021
United States, Oklahoma
Health Reserarch Institute
Oklahoma City, Oklahoma, United States, 73109
United States, Pennsylvania
Hand Microsurgery and Reconstructive Orthopaedics
Erie, Pennsylvania, United States, 16507
Australia, Queensland
Peninsula Private Hospital
Kippa Ring, Queensland, Australia, 4021
AusTrials Sherwood
Sherwood, Queensland, Australia, 4075
Australia, Victoria
Emeritus Research
Malvern East, Victoria, Australia, 3145
Uppsala Akademiska University Hospital
Uppsala, SE, Sweden, SE-751
United Kingdom
Pulvertaft Hand Center
Derby, GB, United Kingdom, DE22 3NE
Newcastle Upon Tyne Hospitals
Newcastle, GB, United Kingdom, NE1 4LP
Sponsors and Collaborators
Auxilium Pharmaceuticals
Study Director: Gregory Kaufman, MD Auxilium Pharmaceuticals, Inc
  More Information

No publications provided

Responsible Party: Auxilium Pharmaceuticals Identifier: NCT01498640     History of Changes
Other Study ID Numbers: AUX-CC-862
Study First Received: December 17, 2011
Results First Received: February 4, 2015
Last Updated: February 4, 2015
Health Authority: United States: Food and Drug Administration
Australia: Therapeutic Goods Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Sweden: Medical Products Agency

Keywords provided by Auxilium Pharmaceuticals:
Dupuytren's disease

Additional relevant MeSH terms:
Dupuytren Contracture
Connective Tissue Diseases
Joint Diseases
Muscular Diseases
Musculoskeletal Diseases processed this record on April 26, 2015